Sartorius Stedim Biotech (FR:DIM) has released an update.
Sartorius Stedim Biotech reported a first-half 2024 revenue of 1,373 million euros, marking a slight decline due to market volatility and conservative customer behavior, particularly in China. Despite a challenging environment, the company achieved a 28.2% EBITDA margin and remains optimistic about the long-term trends in the biopharmaceutical and life sciences sector. Adjusted forecasts reflect a cautious outlook for the year, with revenue expected to remain at the previous year’s level and a current EBITDA margin prediction of 27 to 29%.
For further insights into FR:DIM stock, check out TipRanks’ Stock Analysis page.
